Biotech, Osteoporosis, Life Sciences
Amgen Osteoporosis Drug Reduces Bone Fractures in Pivotal Study
Luke Timmerman 7/25/08
Amgen, the world’s largest biotechnology company, said today that its experimental drug for osteoporosis reduced the rate of fractures in a pivotal clinical trial of 7,800 women who took the drug or a placebo. The rate of side effects, including infections, were similar for patients on denosumab and the placebo, the company said. Thousand Oaks, CA-based Amgen (NASDAQ: AMGN) has about 1,000 employees in Seattle and Bothell. Analysts have predicted the new drug could exceed $2 billion in annual sales if approved by the FDA.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
